|
Breast Cancer genetic study in African-ancestry populations
|
5R01CA202981-02
|
$2,391,119
|
|
ZHENG, WEI
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
SPORE in Lung Cancer
|
5P50CA058187-22
|
$2,300,000
|
|
BUNN, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
|
Specialized Program Of Research Excellence (SPORE) in Leukemia
|
5P50CA171963-05
|
$2,300,000
|
|
LINK, DANIEL
|
WASHINGTON UNIVERSITY
|
|
Risk of Pediatric and Adolescent Cancer Associated with Medical Imaging
|
5R01CA185687-03
|
$2,177,040
|
|
SMITH-BINDMAN, REBECCA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Imaging and Tissue Correlates to Optimize Management of Glioblastoma
|
5P01CA118816-10
|
$2,175,899
|
|
CHANG, SUSAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Moffitt Skin Cancer SPORE
|
5P50CA168536-05
|
$1,789,062
|
|
SONDAK, VERNON
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Investigating the development of AIDs and non-AIDS defining cancers in aged SIV-infected rhesus macaques.
|
5R01CA206404-02
|
$1,555,244
|
|
WONG, SCOTT
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Defining RAS isoform- and mutation-specific roles in oncogenesis
|
5P01CA203657-02
|
$1,542,424
|
|
DER, CHANNING
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
The Biology of Prostate Cancer Skeletal Metastases
|
5P01CA093900-13
|
$1,510,770
|
|
KELLER, EVAN
|
UNIVERSITY OF MICHIGAN
|
|
Direct and Repeated Clinical Measurement of pO2 for Enhancing Cancer Therapy
|
5P01CA190193-03
|
$1,372,998
|
|
SWARTZ, HAROLD
|
DARTMOUTH COLLEGE
|
|
Molecular Mechanism of Action of Phorbol Ester
|
Z01 BC 005270
|
$1,250,284
|
$62,514
|
Blumberg, Peter
|
CCR (NCI)
|
|
High-throughput sequencing to identify novel melanoma susceptibility genes
|
5R01CA195614-03
|
$1,075,388
|
|
HUFF, CHAD
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Commercializing Praedicare Dx TM platform for guiding cancer treatments
|
2R44CA203610-02A1
|
$998,807
|
|
CARDONE, MICHAEL
|
EUTROPICS PHARMACEUTICALS, INC.
|
|
A Novel PET Probe for Use in Cancer Diagnostics
|
2R44CA216539-02
|
$997,667
|
|
MOORE, MELISSA
|
SOFIE BIOSCIENCES, INC.
|
|
Using markers to improve pancreatic cancer screening and surveillance
|
5U01CA210170-02
|
$953,081
|
|
GOGGINS, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
|
Cancer and Context
|
5R35CA197571-03
|
$941,316
|
|
MACARA, IAN
|
VANDERBILT UNIVERSITY
|
|
Comparative Effectiveness of Fecal Immunochemical Tests with Optical Colonoscopy
|
1R01CA215034-01
|
$940,235
|
|
LEVY, BARCEY
|
UNIVERSITY OF IOWA
|
|
A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery
|
5R44CA211013-02
|
$937,091
|
|
LEE, W DAVID
|
LUMICELL DIAGNOSTICS, INC.
|
|
Mutations of Chromatin and its Modifying Machineries in Malignancies
|
5R35CA197569-03
|
$919,663
|
|
SHILATIFARD, ALI
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy
|
5R35CA197450-03
|
$913,955
|
|
PETER, MARCUS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The mTOR and Hippo pathway in cell growth and cancer
|
5R35CA196878-03
|
$912,964
|
|
GUAN, KUN-LIANG
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer
|
5U01CA210138-02
|
$898,049
|
|
PETERSEN, GLORIA
|
MAYO CLINIC ROCHESTER
|
|
Systems Modeling of Tumor Heterogeneity and Therapy Response in Colorectal Cancer
|
1R01CA208179-01A1
|
$853,654
|
|
GINTY, FIONA
|
GENERAL ELECTRIC GLOBAL RESEARCH CTR
|
|
Building protected data sharing networks to advance cancer risk assessment and treatment
|
1U24CA209996-01A1
|
$805,856
|
|
FOSTER, IAN
|
UNIVERSITY OF CHICAGO
|
|
OSU K12 Training Grant for Clinical Faculty Investigators
|
5K12CA133250-09
|
$797,702
|
|
BYRD, JOHN
|
OHIO STATE UNIVERSITY
|
|
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
|
5U01CA210171-02
|
$794,139
|
|
WOLPIN, BRIAN
|
DANA-FARBER CANCER INST
|
|
Improving Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
|
5R01CA193673-02
|
$773,975
|
|
SHELBY, REBECCA
|
DUKE UNIVERSITY
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-02
|
$772,521
|
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
A high efficiency imager for real-time lung cancer monitoring during radiotherapy
|
5R01CA188446-04
|
$768,460
|
|
BERBECO, ROSS
|
DANA-FARBER CANCER INST
|
|
Scalable Clinical Decision Support for Individualized Cancer Risk Management
|
1U24CA204800-01A1
|
$766,250
|
|
DEL FIOL, GUILHERME
|
UNIVERSITY OF UTAH
|
|
Treatment decision making in low-risk thyroid cancer
|
5R01CA201198-02
|
$759,437
|
|
HAYMART, MEGAN
|
UNIVERSITY OF MICHIGAN
|
|
Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy
|
1U01CA215798-01
|
$739,468
|
|
LAUFFENBURGER, DOUGLAS
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Oral Microbiome and Lung Cancer Risk
|
5R01CA207466-02
|
$731,073
|
|
CAI, QIUYIN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
In vivo imaging of single circulating cells
|
5R01CA186567-06
|
$717,674
|
|
WANG, LIHONG
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Integrative approach to heterogeneity in breast cancer metastasis
|
5U01CA199315-02
|
$713,777
|
|
WERB, ZENA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Open Architecture Image-Guided Therapy Software System
|
5R44CA115263-03
|
$713,066
|
$71,307
|
Stefansic, James
|
PATHFINDER THERAPEUTICS
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
1R01CA216273-01
|
$701,924
|
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
[PQC-3] A Metabolic Pathway Activation Marker for Prostate Cancer Prognosis
|
5R01CA185251-04
|
$700,207
|
|
BEEBE, DAVID
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Precision Medicine Approach to Prostate Cancer Active Surveillance
|
5R01CA184712-04
|
$695,027
|
|
MOSQUERA, JUAN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Multiscale Modeling of Bone Environment Responses to Metastatic Prostate Cancer
|
5U01CA202958-02
|
$690,824
|
|
BASANTA GUTIERREZ, DAVID
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
High Throughput Screening to Discover Chemical Inhibitors of Quiescin Sulfhydryl Oxidase 1
|
5R01CA201226-02
|
$678,423
|
|
FAIGEL, DOUGLAS
|
MAYO CLINIC ARIZONA
|
|
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy
|
5R01CA204924-02
|
$669,635
|
|
BLASBERG, RONALD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
|
5R01CA198089-03
|
$663,135
|
|
CARROLL, MARTIN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Genetic Epidemiology of non-Hodgkin Lymphoma
|
5R01CA200703-02
|
$662,837
|
|
CERHAN, JAMES
|
MAYO CLINIC ROCHESTER
|
|
Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake
|
5R01CA210125-02
|
$656,491
|
|
WOODALL, W
|
KLEIN BUENDEL, INC.
|
|
Analysis of Tobacco Industry Documents
|
5R01CA087472-18
|
$655,138
|
|
GLANTZ, STANTON
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Large-Area Plasma Panel Detectors for Particle Beam Radiation Therapy
|
5R44CA183437-03
|
$650,488
|
|
FRIEDMAN, PETER
|
INTEGRATED SENSORS, LLC
|
|
Genome-wide Pleiotropy Scan across Multiple Cancers
|
5R01CA201358-02
|
$648,968
|
|
WITTE, JOHN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Novel immunological biomarkers ovarian cancer prognosis
|
5R01CA188900-03
|
$646,389
|
|
SEGAL, BRAHM
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Program for Training in Cancer Epidemiology
|
5T32CA009001-42
|
$642,687
|
|
STAMPFER, MEIR
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
Total relevant funding to Ear for this search: $225,018
|